Scroll

adenosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	90	58-61-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: adenosine adenine riboside riboadenosine beta-Adenosine beta-D-Adenosine adenoscan	A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Molecular weight: 267.25 Formula: C10H13N5O4 CLOGP: -1.36 LIPINSKI: 0 HAC: 9 HDO: 4 TPSA: 139.54 ALOGS: -1.28 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

adenosine
adenine riboside
riboadenosine
beta-Adenosine
beta-D-Adenosine
adenoscan

A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.

Molecular weight: 267.25
Formula: C10H13N5O4
CLOGP: -1.36
LIPINSKI: 0
HAC: 9
HDO: 4
TPSA: 139.54
ALOGS: -1.28
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	5 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.48 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Oct. 30, 1989	FDA	ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Supraventricular tachycardia	45.50	24.06	17	1737	12784	50590586
Atrial fibrillation	44.57	24.06	33	1721	101712	50501658
Pneumonia aspiration	42.61	24.06	21	1733	30983	50572387
Ventricular tachycardia	42.00	24.06	17	1737	15804	50587566
Coma	33.16	24.06	22	1732	56857	50546513
Exfoliative rash	32.79	24.06	9	1745	2521	50600849
Underdose	31.67	24.06	15	1739	20263	50583107
Ventricular fibrillation	30.29	24.06	12	1742	10547	50592823
Drug ineffective	29.93	24.06	78	1676	819255	49784115
Bronchospasm	29.53	24.06	13	1741	14841	50588529
Gastrooesophageal reflux disease	29.48	24.06	23	1731	76405	50526965
Toxic epidermal necrolysis	28.18	24.06	14	1740	20978	50582392
Tachycardia induced cardiomyopathy	26.32	24.06	4	1750	55	50603315
Tachycardia	26.08	24.06	24	1730	99739	50503631
Arteriospasm coronary	25.87	24.06	8	1746	3394	50599976
Cardiogenic shock	25.78	24.06	12	1742	15587	50587783
Ventricular asystole	25.26	24.06	4	1750	73	50603297

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchospasm	94.60	23.82	30	1459	9579	29563459
Oesophageal ulcer haemorrhage	66.87	23.82	11	1478	174	29572864
Ventricular tachycardia	53.60	23.82	25	1464	22549	29550489
Drug ineffective	45.96	23.82	72	1417	363098	29209940
Mallory-Weiss syndrome	45.67	23.82	11	1478	1266	29571772
Supraventricular tachycardia	36.66	23.82	15	1474	9869	29563169
Myositis	32.74	23.82	14	1475	10269	29562769
Complex regional pain syndrome	32.56	23.82	7	1482	484	29572554
Gingival bleeding	31.68	23.82	12	1477	6441	29566597
Ventricular fibrillation	29.89	23.82	15	1474	15818	29557220
Rebound tachycardia	28.77	23.82	4	1485	18	29573020

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchospasm	115.59	21.68	42	2982	21640	64474068
Ventricular tachycardia	80.88	21.68	37	2987	34228	64461480
Supraventricular tachycardia	73.17	21.68	29	2995	18878	64476830
Ventricular fibrillation	57.02	21.68	26	2998	23834	64471874
Drug ineffective	55.30	21.68	121	2903	840126	63655582
Oesophageal ulcer haemorrhage	54.93	21.68	11	3013	577	64495131
Atrial fibrillation	49.81	21.68	50	2974	171039	64324669
Arteriospasm coronary	46.34	21.68	15	3009	5450	64490258
Mallory-Weiss syndrome	38.74	21.68	11	3013	2572	64493136
Exfoliative rash	35.30	21.68	11	3013	3535	64492173
Tachycardia induced cardiomyopathy	34.96	21.68	6	3018	133	64495575
Cardiac arrest	34.16	21.68	39	2985	154025	64341683
Cardiogenic shock	30.56	21.68	19	3005	32408	64463300
Myositis	27.44	21.68	14	3010	16363	64479345
Drug ineffective for unapproved indication	26.24	21.68	17	3007	31116	64464592
Gingival bleeding	25.77	21.68	13	3011	14841	64480867
Complex regional pain syndrome	24.43	21.68	7	3017	1689	64494019
Pneumonia aspiration	24.31	21.68	21	3003	59250	64436458
Underdose	23.99	21.68	15	3009	25814	64469894

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01EB10	CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations
MeSH PA	D000700	Analgesics
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D058913	Purinergic Agonists
MeSH PA	D058906	Purinergic P1 Receptor Agonists
MeSH PA	D018689	Sensory System Agents
MeSH PA	D014665	Vasodilator Agents
FDA MoA	N0000175788	Adenosine Receptor Agonists
FDA EPC	N0000178375	Adenosine Receptor Agonist
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:38070	antiarrhythmic agent
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:78675	fundamental metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Paroxysmal supraventricular tachycardia	indication	67198005
Myocardial Perfusion Imaging Adjunct	indication
Supraventricular tachycardia	off-label use	6456007
Pericarditis	contraindication	3238004	DOID:1787
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Disorder of autonomic nervous system	contraindication	15241006
Complete atrioventricular block	contraindication	27885002
Hypovolemia	contraindication	28560003
Acute cerebrovascular insufficiency	contraindication	29322000
Transplantation of heart	contraindication	32413006
Sick sinus syndrome	contraindication	36083008	DOID:13884
Low blood pressure	contraindication	45007003
Aortic valve stenosis	contraindication	60573004	DOID:1712
Left to right cardiovascular shunt	contraindication	66130006
Mitral valve stenosis	contraindication	79619009	DOID:1754
Pulmonary emphysema	contraindication	87433001
Respiratory alkalosis	contraindication	111378004
Second degree atrioventricular block	contraindication	195042002
Asthma	contraindication	195967001	DOID:2841
Left main coronary artery disease	contraindication	371804009
Acute coronary syndrome	contraindication	394659003
Respiratory insufficiency	contraindication	409623005
Syncope due to Bradycardia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.67	acidic
pKa2	12.33	acidic
pKa3	13.34	acidic
pKa4	3.95	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Adenosine receptor A2b	GPCR	P29275	AA2BR_HUMAN	AGONIST	EC50	4.62	WOMBAT-PK	CHEMBL
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN	AGONIST	EC50	6.16	WOMBAT-PK	CHEMBL
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN	AGONIST	EC50	6.51	WOMBAT-PK	CHEMBL
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	5.36	CHEMBL
Adenosylhomocysteinase	Enzyme	P23526	SAHH_HUMAN		Km	5.80	WOMBAT-PK
Phosphatidylinositol 4-kinase type 2-alpha	Kinase	Q9BTU6	P4K2A_HUMAN	INHIBITOR	IC50	5	IUPHAR
Phosphatidylinositol 4-kinase type 2-beta	Kinase	Q8TCG2	P4K2B_HUMAN	INHIBITOR	IC50	5	IUPHAR
Glyceraldehyde-3-phosphate dehydrogenase liver	Enzyme	P04406	G3P_HUMAN		IC50	4.46	CHEMBL
Adenosine deaminase	Enzyme	P00813	ADA_HUMAN		Kd	4.60	WOMBAT-PK
Histone-lysine N-methyltransferase, H3 lysine-79 specific	Enzyme	Q8TEK3	DOT1L_HUMAN		IC50	4	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN	AGONIST	Ki	6.54	IUPHAR
Adenosine kinase	Kinase	P55263	ADK_HUMAN		IC50	6	WOMBAT-PK
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	8.29	CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	7.52	CHEMBL
Adenosine receptor A3	GPCR		AA3R_RAT		Ki	7	CHEMBL
Adenosine kinase	Kinase		ADK_TOXGO		Ki	5.05	CHEMBL
Adenosine A2 receptor	GPCR		AA2BR_RAT AA2AR_RAT		Ki	8.30	CHEMBL
cAMP-dependent protein kinase A	Kinase		KAP2_BOVIN KAPCA_BOVIN KAPCB_BOVIN KAP3_BOVIN		Ki	4.82	CHEMBL

External reference:

ID	Source
4019507	VUID
N0000147627	NUI
D00045	KEGG_DRUG
215025	RXNORM
C0001443	UMLSCUI
CHEBI:16335	CHEBI
ADN	PDB_CHEM_ID
CHEMBL477	ChEMBL_ID
DB00640	DRUGBANK_ID
D000241	MESH_DESCRIPTOR_UI
60961	PUBCHEM_CID
2844	IUPHAR_LIGAND_ID
K72T3FS567	UNII
1072	MMSL
4135	MMSL
57772	MMSL
d00164	MMSL
003603	NDDF
004537	NDDF
004813	NDDF
4019507	VANDF
108502004	SNOMEDCT_US
35431001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9809	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	20 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1932	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	25 sections
Adenocard	HUMAN PRESCRIPTION DRUG LABEL	1	0469-8234	SOLUTION	3 mg	INTRAVENOUS	NDA	17 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6113	INJECTION	3 mg	INTRAVENOUS	ANDA	21 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0703-8776	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	0703-8777	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-180	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-972	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	27 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-542	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	21 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-542	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	21 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-544	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	26 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-953	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	20 sections
Adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	23155-258	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	25 sections
Too im Cell ALL IN ONE	HUMAN OTC DRUG LABEL	3	24765-124	LOTION	0.40 mg	TOPICAL	OTC monograph not final	8 sections
adenosine	HUMAN PRESCRIPTION DRUG LABEL	1	25021-301	INJECTION	3 mg	INTRAVENOUS	ANDA	23 sections
Tissen NF 10	HUMAN OTC DRUG LABEL	1	42491-1100	LIQUID	0.01 g	TOPICAL	unapproved drug other	8 sections
Tissen ICM 10	HUMAN OTC DRUG LABEL	1	42491-1200	LIQUID	0.01 g	TOPICAL	unapproved drug other	8 sections
Dr G deWrinkle BOOSTER ample by EGF	HUMAN OTC DRUG LABEL	2	43948-3001	SOLUTION/ DROPS	0.04 mL	TOPICAL	OTC monograph final	4 sections
Dr G deWrinkle FORTIFIER by EGF	HUMAN OTC DRUG LABEL	2	43948-3002	CREAM	0.01 mL	TOPICAL	OTC monograph final	4 sections
Dr G deWrinkle REFORMER by EGF	HUMAN OTC DRUG LABEL	2	43948-3003	CREAM	0.02 mL	TOPICAL	OTC monograph final	4 sections
Super Plus Beblesh Balm Triple Functions SPF50 Plus PA 3Plus (40g)	HUMAN OTC DRUG LABEL	6	49715-007	CREAM	0.02 g	TOPICAL	OTC monograph final	10 sections
The Prestige BB SPF25 PA 2Plus	HUMAN OTC DRUG LABEL	4	49715-008	CREAM	0.02 g	TOPICAL	OTC monograph final	10 sections
The Oriental Gold BB SPF25 PA 2Plus	HUMAN OTC DRUG LABEL	4	49715-010	CREAM	0.02 g	TOPICAL	OTC monograph final	10 sections
Absolute Total BB SPF37 PA 3Plus	HUMAN OTC DRUG LABEL	4	49715-011	CREAM	0.02 g	TOPICAL	OTC monograph final	10 sections
SuperPlus Beblesh Balm Triple Functions SPF25 PA 2Plus	HUMAN OTC DRUG LABEL	6	49715-014	CREAM	0.02 g	TOPICAL	OTC monograph final	10 sections
SuperPlus Beblesh Balm Gold SPF25 PA 2Plus	HUMAN OTC DRUG LABEL	4	49715-015	CREAM	0.01 g	TOPICAL	OTC monograph final	10 sections
SuperPlus Beblesh Balm Gold SPF25 PA 2Plus	HUMAN OTC DRUG LABEL	6	49715-016	CREAM	0.02 g	TOPICAL	OTC monograph final	10 sections
SuperPlus Beblesh Balm SPF25 PA 2Plus	HUMAN OTC DRUG LABEL	4	49715-017	CREAM	0.01 g	TOPICAL	OTC monograph final	10 sections
SuperPlus Beblesh Balm SPF25 PA 2Plus	HUMAN OTC DRUG LABEL	6	49715-018	CREAM	0.02 g	TOPICAL	OTC monograph final	10 sections
SKIN79 SNAIL NUTRITION BBCREAM	HUMAN OTC DRUG LABEL	5	49715-019	CREAM	0.02 g	TOPICAL	OTC monograph final	3 sections